RP-3 by Replimune for Lung Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025

The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman’s Health Imperative-and the National

February 28, 2025

Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results

Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results. While

March 2, 2024

Genetically altered pig heart transplanted into a human for the second time

In a new test of xenotransplantation, a medical team at the University of Maryland Medical Center announced Friday that, for only the second time in

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.